Phase II Trial of Cabozantinib in Recurrent/Metastatic Endometrial Cancer: A Study of the Princess Margaret, Chicago and California Consortia (NCI9322/PHL86).

CONCLUSIONS: Cabozantinib has activity in serous and endometrioid histology EC. These results support further evaluation in genomically characterized patient cohorts.
PMID: 31992589 [PubMed - as supplied by publisher]

Source: Clinical Cancer Research - January 27, 2020 Category: Cancer & Oncology Authors: Dhani NC, Hirte HW, Wang L, Burnier JV, Jain A, Butler MO, Welch S, Fleming GF, Hurteau J, Matsuo K, Matei D, Jimenez W, Johnston C, Cristea M, Tonkin K, Ghatage P, Lheureux S, Mehta A, Quintos J, Tan Q, Kamel-Reid S, Ludkovski O, Tsao MS, Wright JJ, Oza Tags: Clin Cancer Res Source Type: research